Kintara Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

TuHURA Biosciences

14/11/2022 14:31

* Kintara Therapeutics Inc  KTRA.OQ  reported a quarterly
adjusted
loss of $3.50​​ per share for the quarter ended in September.
The lone analyst forecast for the quarter was for breakeven
results per share.
    * Reported revenue was zero​; analysts expected $4.71
million. 
    * Kintara Therapeutics Inc's reported EPS for the quarter
was a
loss of $3.50​.
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Kintara Therapeutics Inc shares had risen by 3,793.5% this
quarter and gained 724.5% so far this year.
    * The company reported a quarterly loss of $4.6 million.
    * Wall Street's median 12-month price target for Kintara
Therapeutics Inc is $150.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
14 at 02:31 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      0.00           -3.50          Missed
 Jun. 30 2022      -1.50          -5.50          Missed
 Mar. 31 2022      -7.50          -5.50          Beat
 Dec. 31 2021      -8.00          -6.00          Beat